Protein Information

ID 1769
Name melanoma associated antigen
Synonyms CLL associated antigen KW 1; CLL associated antigen KW 1 splice variant 1; CLL associated antigen KW 1 splice variant 2; Melanoma associated antigen; CLL associated antigen KW 1 splice variant 1s; CLL associated antigen KW 1 splice variant 2s; Melanoma associated antigens

Compound Information

ID 864
Name MAA
CAS methylarsonic acid

Reference

PubMed Abstract RScore(About this table)
16455987 Peng L, Ko E, Luo W, Wang X, Shrikant PA, Ferrone S: CD4-dependent potentiation of a high molecular weight-melanoma-associated antigen-specific CTL response elicited in HLA-A2/Kb transgenic mice. J Immunol. 2006 Feb 15;176(4):2307-15.
The human high m.w.-melanoma-associated Ag (HMW-MAA) is an attractive target for the immunotherapy of melanoma, due to its relatively high expression in a high percentage of melanoma lesions and its restricted distribution in normal tissues. Active immunization with HMW-MAA mimics has been previously shown to induce a HMW-MAA-specific, T cell-dependent Ab response associated with an apparent clinically beneficial effect in advanced melanoma patients. Although T cells play an important role in controlling tumor growth, only limited information is available to date about the induction of HMW-MAA-specific CTL. In this report, we show that immunization of HLA-A2/K (b) transgenic mice with HMW-MAA cDNA-transfected syngeneic dendritic cells elicited a CD8 (+) CTL response specific for HMW-MAA peptides with HLA-A2 Ag-binding motifs. The elicited CTL lysed HLA-A2 (+) HMW-MAA (+) melanoma cells in vitro, and mouse HLA-A2/K (b) cells pulsed with HMW-MAA-derived peptides in vitro and in vivo. Although this CTL response could be generated in the absence of CD4 (+) T cell help, harnessing CD4 (+) T cell help in a noncognate Ag-specific manner with the polyclonal activator staphylococcal enterotoxin A augmented the CTL response. These results imply that dendritic cell-based immunization, in combination with CD4 (+) T cell help, represents an effective strategy to implement T cell-based immunotherapy targeting HMW-MAA in patients with HMW-MAA-bearing tumors.
1(0,0,0,1)